Pharmacoeconomics, 1170-7690

Journal

  1. 2019
  2. Kent, S., Becker, F., Feenstra, T., Tran-Duy, A., Schlackow, I., Tew, M., Zhang, P., Ye, W., Lizheng, S., Herman, W., McEwan, P., Schramm, W., Gray, A., Leal, J., Lamotte, M., Willis, M., Palmer, A. J., & Clarke, P. (2019). The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood. Pharmacoeconomics, 37(11), 1305-1312. https://doi.org/10.1007/s40273-019-00825-1
  3. 2018
  4. Makady, A., van Veelen, A., Jonsson, P., Moseley, O., D'Andon, A., de Boer, A., Hillege, H., Klungel, O., & Goettsch, W. (2018). Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies. Pharmacoeconomics, 36(3), 359-368. https://doi.org/10.1007/s40273-017-0596-z
  5. 2017
  6. 2016
  7. Dolk, C., Eichner, M., Welte, R., Anastassopoulou, A., Van Bellinghen, L-A., Nautrup, B. P., Van Vlaenderen, I., Schmidt-Ott, R., Schwehm, M., & Postma, M. (2016). Cost-Utility of Quadrivalent Versus Trivalent Influenza Vaccine in Germany, Using an Individual-Based Dynamic Transmission Model. Pharmacoeconomics, 34(12), 1299-1308. https://doi.org/10.1007/s40273-016-0443-7
  8. Dunlop, W. C. N., Mullins, C. D., Pirk, O., Goeree, R., Postma, M. J., Enstone, A., & Heron, L. (2016). BEACON: A Summary Framework to Overcome Potential Reimbursement Hurdles. Pharmacoeconomics, 34(10), 1051-1065. https://doi.org/10.1007/s40273-016-0427-7
  9. Ultsch, B., Damm, O., Beutels, P., Bilcke, J., Brueggenjuergen, B., Gerber-Grote, A., Greiner, W., Hanquet, G., Hutubessy, R., Jit, M., Knol, M., von Kries, R., Kuhlmann, A., Levy-Bruhl, D., Perleth, M., Postma, M., Salo, H., Siebert, U., Wasem, J., & Wichmann, O. (2016). Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community. Pharmacoeconomics, 34(3), 227-244. https://doi.org/10.1007/s40273-015-0335-2
  10. Bindels, J., Ramaekers, B., Ramos, I. C., Mohseninejad, L., Knies, S., Grutters, J., Postma, M., Al, M., Feenstra, T., & Joore, M. (2016). Use of Value of Information in Healthcare Decision Making: Exploring Multiple Perspectives. Pharmacoeconomics, 34(3), 315-322. https://doi.org/10.1007/s40273-015-0346-z
  11. 2015
  12. Marshall, D. A., Burgos-Liz, L., Pasupathy, K. S., Padula, W. V., IJzerman, M. J., Wong, P. K., Higashi, M. K., Engbers, J., Wiebe, S., Crown, W., & Osgood, N. D. (2015). Transforming Healthcare Delivery: Integrating Dynamic Simulation Modelling and Big Data in Health Economics and Outcomes Research. Pharmacoeconomics. https://doi.org/10.1007/s40273-015-0330-7
  13. 2014
  14. 2013
  15. Armstrong, N., Joore, M., van Asselt, T., Misso, K., Manning, N., Tomini, F., Kleijnen, J., & Riemsma, R. (2013). Golimumab for the treatment of ankylosing spondylitis: A NICE single technology appraisal. Pharmacoeconomics, 31(5), 415-425. https://doi.org/10.1007/s40273-013-0049-2
  16. 2012
  17. 2011
  18. van Baal, P. H. M., Wong, A., Slobbe, L. C. J., Polder, J. J., Brouwer, W. B. F., & de Wit, G. A. (2011). Standardizing the Inclusion of Indirect Medical Costs in Economic Evaluations. Pharmacoeconomics, 29(3), 175-187.
  19. 2009
  20. Van Asselt, A. D. I., Van Mastrigt, G. A. P. G., Dirksen, C. D., Arntz, A., Severens, J. L., & Kessels, A. G. H. (2009). How to deal with cost differences at baseline. Pharmacoeconomics, 27(6), 519-528. https://doi.org/10.2165/00019053-200927060-00007
  21. 2008
  22. de Vries, R., Daenen, S., Tolley, K., Glasmacher, A., Prentice, A., Howells, S., Christopherson, H., de Jong-van den Berg, L. T., & Postma, M. J. (2008). Cost effectiveness of itraconazole in the prophylaxis of invasive fungal infections. Pharmacoeconomics, 26(1), 75-90.
  23. Heeg, B. M. S., Damen, J., Buskens, E., Caleo, S., de Charro, F., & van Hout, B. A. (2008). Modelling approaches - The case of schizophrenia: the case of schizophrenia. Pharmacoeconomics, 26(8), 633-648.
  24. 2007
  25. 2006
  26. Oude Voshaar, R. C., Krabbe, P. F. M., Gorgels, W. J. M. J., Adang, E. M. M., van Balkom, A. J. L. M., van de Lisdonk, E. H., & Zitman, F. G. (2006). Tapering off benzodiazepines in long-term users: an economic evaluation. Pharmacoeconomics, 24(7), 683-694.
  27. 2005
  28. 2004
  29. Tramarin, A., Campostrini, S., Postma, M., Calleri, G., Tolley, K., Parise, N., & de Lalla, F. (2004). A Multicentre Study of Patient Survival, Disability, Quality of life and Cost of Care. Pharmacoeconomics, 22(1), 43 - 53.
  30. Tramarin, A., Campostrini, S., Postma, MJ., Calleri, G., Tolley, K., Parise, N., de Lalla, F., & Palladio Study Grp (2004). A multicentre study of patient survival, disability, quality of life and cost of care - Among patients with AIDS in northern Italy. Pharmacoeconomics, 22(1), 43-53.
Previous 1 2 Next

ID: 729269